Biological treatment in severe Still's disease--a case report
Still's disease and systemic juvenile idiopathic arthritis (JIA) are multisystem inflammatory diseases of unknown etiology, different disease course and prognosis. Still's disease is characterized by hectic fever, arthritis, skin rash, organomegaly, elevated serum ferritin and inflammatory factors. Early diagnosis and intensive treatment can prevent disease progression and reduce complications such as amyloidosis, physical disability. The first choice of treatment are high doses of corticosteroids and synthetic disease-modifying drugs (DMARDs), including methotrexate (MTX), cyclosporine (CsA). Biologic agents are second line therapy when DMARDs aren't effective, e.g. monoclonal antibodies blocking the action of TNF-alpha (anti-TNF-α), interleukin-1 (ANK--anakinra) and interleukin-6 (TCZ--tocilizumab). We describe in details treatment strategies applied in a young woman with severe Still's disease treated with combination therapy of DMARDs and anti-TNF-α, including etanercept (ETA) or certolizumab (CER). TCZ was applied for the treatment of Still's disease following treatment failure with anti-TNF-α. We've achieved a complete remission of the Still's disease during treatment TCZ.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:68 |
|---|---|
| Enthalten in: |
Wiadomosci lekarskie (Warsaw, Poland : 1960) - 68(2015), 1 vom: 01., Seite 104-7 |
| Sprache: |
Polnisch |
|---|
| Weiterer Titel: |
Leczenie biologiczne w ciqikiej postaci choroby Stilla--opis przypadku |
|---|
| Beteiligte Personen: |
Suszek, Dorota [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 02.07.2015 Date Revised 03.12.2018 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM250151510 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM250151510 | ||
| 003 | DE-627 | ||
| 005 | 20231224155120.0 | ||
| 007 | tu | ||
| 008 | 231224s2015 xx ||||| 00| ||pol c | ||
| 028 | 5 | 2 | |a pubmed24n0833.xml |
| 035 | |a (DE-627)NLM250151510 | ||
| 035 | |a (NLM)26094343 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a pol | ||
| 100 | 1 | |a Suszek, Dorota |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Biological treatment in severe Still's disease--a case report |
| 246 | 3 | 3 | |a Leczenie biologiczne w ciqikiej postaci choroby Stilla--opis przypadku |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 02.07.2015 | ||
| 500 | |a Date Revised 03.12.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Still's disease and systemic juvenile idiopathic arthritis (JIA) are multisystem inflammatory diseases of unknown etiology, different disease course and prognosis. Still's disease is characterized by hectic fever, arthritis, skin rash, organomegaly, elevated serum ferritin and inflammatory factors. Early diagnosis and intensive treatment can prevent disease progression and reduce complications such as amyloidosis, physical disability. The first choice of treatment are high doses of corticosteroids and synthetic disease-modifying drugs (DMARDs), including methotrexate (MTX), cyclosporine (CsA). Biologic agents are second line therapy when DMARDs aren't effective, e.g. monoclonal antibodies blocking the action of TNF-alpha (anti-TNF-α), interleukin-1 (ANK--anakinra) and interleukin-6 (TCZ--tocilizumab). We describe in details treatment strategies applied in a young woman with severe Still's disease treated with combination therapy of DMARDs and anti-TNF-α, including etanercept (ETA) or certolizumab (CER). TCZ was applied for the treatment of Still's disease following treatment failure with anti-TNF-α. We've achieved a complete remission of the Still's disease during treatment TCZ | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 650 | 7 | |a Immunoglobulin Fab Fragments |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a Receptors, Tumor Necrosis Factor |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 650 | 7 | |a Polyethylene Glycols |2 NLM | |
| 650 | 7 | |a 3WJQ0SDW1A |2 NLM | |
| 650 | 7 | |a tocilizumab |2 NLM | |
| 650 | 7 | |a I031V2H011 |2 NLM | |
| 650 | 7 | |a Etanercept |2 NLM | |
| 650 | 7 | |a OP401G7OJC |2 NLM | |
| 650 | 7 | |a Certolizumab Pegol |2 NLM | |
| 650 | 7 | |a UMD07X179E |2 NLM | |
| 650 | 7 | |a Methotrexate |2 NLM | |
| 650 | 7 | |a YL5FZ2Y5U1 |2 NLM | |
| 700 | 1 | |a Koszarny, Arkadiusz |e verfasserin |4 aut | |
| 700 | 1 | |a Jeleniewicz, Radosław |e verfasserin |4 aut | |
| 700 | 1 | |a Majdan, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Bończak, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Czukiewska, Agnieszka |e verfasserin |4 aut | |
| 700 | 1 | |a Koszła, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Kurlej, Sylwia |e verfasserin |4 aut | |
| 700 | 1 | |a Markowicz, Justyna |e verfasserin |4 aut | |
| 700 | 1 | |a Szymczyk, Agnieszka |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Wiadomosci lekarskie (Warsaw, Poland : 1960) |d 1960 |g 68(2015), 1 vom: 01., Seite 104-7 |w (DE-627)NLM00001138X |x 0043-5147 |7 nnns |
| 773 | 1 | 8 | |g volume:68 |g year:2015 |g number:1 |g day:01 |g pages:104-7 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 68 |j 2015 |e 1 |b 01 |h 104-7 | ||